News
CRL
168.22
-0.94%
-1.59
Charles River Labs downgraded at William Blair on less early-stage R&D spending
Seeking Alpha · 19h ago
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
NASDAQ · 21h ago
This STMicroelectronics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Benzinga · 22h ago
Charles River Labs Cut to Market Perform From Outperform by William Blair
Dow Jones · 22h ago
William Blair Downgrades Charles River to Market Perform
Benzinga · 22h ago
Charles River downgraded to Market Perform from Outperform at William Blair
TipRanks · 23h ago
Weekly Report: what happened at CRL last week (0113-0117)?
Weekly Report · 3d ago
What Moved Markets This Week
Seeking Alpha · 4d ago
Charles River Labs downgraded to neutral by UBS
Seeking Alpha · 5d ago
Salesforce upgraded, Southwest downgraded: Wall Street’s top analyst calls
TipRanks · 5d ago
This Spotify Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Benzinga · 5d ago
Charles River Labs: Near A Fundamental Trough, Growth  Should Reignite Again
Seeking Alpha · 5d ago
Upslope Capital's Q4 2024 Investor Letter
Seeking Alpha · 5d ago
Charles River Labs Price Target Cut to $185.00/Share From $250.00 by UBS
Dow Jones · 5d ago
Charles River Labs Cut to Neutral From Buy by UBS
Dow Jones · 5d ago
UBS Downgrades Charles River to Neutral, Lowers Price Target to $185
Benzinga · 5d ago
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line?
NASDAQ · 5d ago
Charles River downgraded to Neutral from Buy at UBS
TipRanks · 6d ago
Hold Rating for Charles River Labs Amid Supply Chain Challenges and Mitigation Strategies
TipRanks · 6d ago
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors
MarketWatch · 6d ago
More
Webull provides a variety of real-time CRL stock news. You can receive the latest news about Charles Riv Labs Intl Inc through multiple platforms. This information may help you make smarter investment decisions.
About CRL
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.